Breaking Through on Biosimilars: Delivering More-Affordable, Innovative Medicines for America’s Patients

Thursday July 26, 2018

Please join us on Thursday, July 26th at noon for a lunch briefing hosted by the Association for Accessible Medicines (AAM) and its Biosimilars Council to learn more about the promise that biosimilars offer to patients and the health care system, and the challenges to the nascent market. 

Today, while just 2 percent of the U.S. patient population uses biologics, these products still account for 26 percent of national prescription drug spending–a record $453 billion in 2017, with utilization of these innovative and very costly medicines expected to grow exponentially in the coming years. Biosimilars offer a much-needed alternative, and these advanced treatments are poised to become available at a lower cost to the millions of U.S. patients seeking access to more-affordable versions of biologic medicines to treat their complex and chronic diseases. But whether the promise of biosimilars will be fulfilled for patients is largely dependent on a regulatory, legislative and market landscape for biosimilars that encourages competition and biosimilar development so that America’s patients can benefit from these life-saving therapies.

Join us for in-depth briefing and discussion with representatives from AAM and the Council’s member companies about how the biosimilars industry is working to realize the full potential of biosimilars and ensure that patients have access to these lower-cost medicines.  Our members will provide their perspective on a number of issues impacting the emerging biosimilar marketplace, including:

  • Biosimilar development & FDA approval process
  • Challenges to bringing biosimilars to market
  • The EU experience
  • Biosimilar education
  • Interchangeability
  • Naming & labeling
  • Reimbursement issues
Who: Patient & Consumer Advocacy, Healthcare Provider, Pharmacist & Health Policy Groups
What: AAM & The Biosimilars Council Lunch Briefing  
When:            Thursday, July 26th from 12:00 – 1:00 p.m.
Where: AAM Offices601 New Jersey Avenue NW, Suite 850, Washington D.C.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.